46 related articles for article (PubMed ID: 23716303)
1. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
Takahashi T; Serada S; Ako M; Fujimoto M; Miyazaki Y; Nakatsuka R; Ikezoe T; Yokoyama A; Taguchi T; Shimada K; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y; Naka T; Nishida T
Int J Cancer; 2013 Dec; 133(11):2737-43. PubMed ID: 23716303
[TBL] [Abstract][Full Text] [Related]
2. Cancer associated fibroblast FAK regulates malignant cell metabolism.
Demircioglu F; Wang J; Candido J; Costa ASH; Casado P; de Luxan Delgado B; Reynolds LE; Gomez-Escudero J; Newport E; Rajeeve V; Baker AM; Roy-Luzarraga M; Graham TA; Foster J; Wang Y; Campbell JJ; Singh R; Zhang P; Schall TJ; Balkwill FR; Sosabowski J; Cutillas PR; Frezza C; Sancho P; Hodivala-Dilke K
Nat Commun; 2020 Mar; 11(1):1290. PubMed ID: 32157087
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
Wada N; Takahashi T; Kurokawa Y; Nakajima K; Nishida T; Koh M; Akamaru Y; Motoori M; Kimura Y; Tanaka K; Miyazaki Y; Makino T; Yamasaki M; Eguchi H; Doki Y
Surg Today; 2021 Sep; 51(9):1506-1512. PubMed ID: 33570662
[TBL] [Abstract][Full Text] [Related]
4. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors.
Amirnasr A; Sleijfer S; Wiemer EAC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32972022
[TBL] [Abstract][Full Text] [Related]
5. A conserved, N-terminal tyrosine signal directs Ras for inhibition by Rabex-5.
Washington C; Chernet R; Gokhale RH; Martino-Cortez Y; Liu HY; Rosenberg AM; Shahar S; Pfleger CM
PLoS Genet; 2020 Jun; 16(6):e1008715. PubMed ID: 32559233
[TBL] [Abstract][Full Text] [Related]
6. Proteomic research in sarcomas - current status and future opportunities.
Burns J; Wilding CP; L Jones R; H Huang P
Semin Cancer Biol; 2020 Apr; 61():56-70. PubMed ID: 31722230
[TBL] [Abstract][Full Text] [Related]
7. Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs.
Amirnasr A; Gits CMM; van Kuijk PF; Smid M; Vriends ALM; Rutkowski P; Sciot R; Schöffski P; Debiec-Rychter M; Sleijfer S; Wiemer EAC
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31238586
[TBL] [Abstract][Full Text] [Related]
8. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Klug LR; Bannon AE; Javidi-Sharifi N; Town A; Fleming WH; VanSlyke JK; Musil LS; Fletcher JA; Tyner JW; Heinrich MC
Oncogene; 2019 Feb; 38(8):1200-1210. PubMed ID: 30242244
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeting
Miyake K; Kawaguchi K; Miyake M; Zhao M; Kiyuna T; Igarashi K; Zhang Z; Murakami T; Li Y; Nelson SD; Bouvet M; Elliott I; Russell TA; Singh AS; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Singh SR; Endo I; Eilber FC; Hoffman RM
Heliyon; 2018 Jun; 4(6):e00643. PubMed ID: 30003151
[TBL] [Abstract][Full Text] [Related]
10. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP
Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941
[No Abstract] [Full Text] [Related]
12. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.
Yoon SM; Haritunians T; Chhina S; Liu Z; Yang S; Landers C; Li D; Ye BD; Shih D; Vasiliauskas EA; Ippoliti A; Rabizadeh S; Targan SR; Melmed GY; McGovern DPB
Inflamm Bowel Dis; 2017 Aug; 23(8):1382-1393. PubMed ID: 28590340
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors.
Obata Y; Horikawa K; Takahashi T; Akieda Y; Tsujimoto M; Fletcher JA; Esumi H; Nishida T; Abe R
Oncogene; 2017 Jun; 36(26):3661-3672. PubMed ID: 28192400
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Takahashi T; Elzawahry A; Mimaki S; Furukawa E; Nakatsuka R; Nakamura H; Nishigaki T; Serada S; Naka T; Hirota S; Shibata T; Tsuchihara K; Nishida T; Kato M
Genes Chromosomes Cancer; 2017 Apr; 56(4):303-313. PubMed ID: 27997714
[TBL] [Abstract][Full Text] [Related]
15. CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.
Tian GA; Zhu CC; Zhang XX; Zhu L; Yang XM; Jiang SH; Li RK; Tu L; Wang Y; Zhuang C; He P; Li Q; Cao XY; Cao H; Zhang ZG
Sci Rep; 2016 Aug; 6():31071. PubMed ID: 27506146
[TBL] [Abstract][Full Text] [Related]
16. Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Frolov A; Evans IM; Li N; Sidlauskas K; Paliashvili K; Lockwood N; Barrett A; Brandner S; Zachary IC; Frankel P
Sci Rep; 2016 Jun; 6():27378. PubMed ID: 27293031
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.
Natatsuka R; Takahashi T; Serada S; Fujimoto M; Ookawara T; Nishida T; Hara H; Nishigaki T; Harada E; Murakami T; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Br J Cancer; 2015 Jul; 113(3):433-42. PubMed ID: 26180928
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
19. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
